Search results
Results From The WOW.Com Content Network
The Medical Injury Compensation Reform Act (MICRA) of 1975 was a statute enacted by the California Legislature in September 1975 [1] and signed into law by Governor Jerry Brown in September. [2] This Act was intended to lower medical malpractice liability insurance premiums for healthcare providers in California by decreasing their potential ...
At the time this settlement was announced in 2014, it was the largest federal settlement with a single company in U.S. history. Bank of America agreed to pay more than $16 billion to resolve ...
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
United States District Court for the Northern District of California: 2010 Luévano v. Campbell: racial bias in written test for employment: Madrigal v. Quilligan: involuntary sterilization: Mauldin v. Wal-Mart Stores: health insurance not covering prescription contraceptives: United States District Court for the Northern District of Georgia ...
GSK on Wednesday said it agreed to settle another lawsuit in California alleging its discontinued heartburn drug Zantac caused cancer, as the British drugmaker sought to end costly litigation that ...
Notably, the model refrains from providing specific projected years or dates. This cautious approach stems from its reliance on 2014 data, preventing precise predictions of the evolving landscape of health insurance programs in subsequent years.
Former Zantac makers GSK, Pfizer, Sanofi and Boehringer Ingelheim are facing about 4,000 claims in California state court and about 2,000 in various other state courts around the country.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...